Erin Dean, MD
Assistant Professor
About Erin Dean
Erin Dean, MD is an Assistant Professor of Medicine in the Division of Hematology and Oncology at the University of Florida College of Medicine.
Dr. Dean received her undergraduate degree in Biomedical Engineering, Premedical, magna cum laude, from the University of California, Irvine and her medical degree from the University of South Florida Morsani College of Medicine in Tampa, Florida.
She finished her residency in Internal Medicine at the University of South Florida Morsani College of Medicine, where she received the Chairman’s Humanism Award for consistently demonstrating compassion, respect, and empathy in the delivery of patient-centered care and service to others. Dr. Dean completed a fellowship in Hematology-Oncology, followed by a dedicated year of training in Blood & Marrow Transplant and Cellular Immunotherapy, at Moffitt Cancer Center.
Her research focuses on the advancement of cellular immunotherapy and the development of new biomedical technology aimed to help patients with malignant hematologic disorders. She is involved in leading clinical trials and conducting translational research within the field. Dr. Dean aims to provide outstanding clinical care for patients with lymphoma and multiple myeloma undergoing CAR T-cell therapy and hematopoietic stem cell transplantation.
Dr. Dean is board certified in Internal Medicine, Medical Oncology, and Hematology. She is a member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO).
Accomplishments
2023 UF Health Cancer Center Physician of the Year
2024
·
University of Florida
Chairman's Humanism Award
2016
·
University of South Florida Health
Outstanding Performance in Doctoring
2011-2012
·
University of South Florida
Teaching Profile
Courses Taught
2022
PAS5010 Intro to Medicine 1
2024
BMS6631 Hematology
Board Certifications
-
HematologyAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
-
Medical OncologyAmerican Board of Internal Medicine
Clinical Profile
Specialties
- Cancer
- Hematology
- Hematology and Oncology
Areas of Interest
- Lymphoma
- Multiple myeloma
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0003-3153-223X
Areas of Interest
- CAR T-cell therapy
- Cellular Immunotherapy
- Hematopoietic Stem Cell Transplantation
- Lymphoma
- Malignant Hematologic Disorders
- Multiple Myeloma
Publications
2024
A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia.
Leukemia & lymphoma.
65(10):1-9
[DOI] 10.1080/10428194.2024.2361111.
[PMID] 38841781.
2024
Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma.
Blood cancer discovery.
5(2):106-113
[DOI] 10.1158/2643-3230.BCD-23-0056.
[PMID] 38194367.
2024
Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report.
Case reports in oncology.
17(1):75-81
[DOI] 10.1159/000535426.
[PMID] 38196817.
2023
Central nervous system manifestations as initial presentation of plasma cell disorders: Differential management of 3 cases based on disease extent
Current Problems in Cancer: Case Reports.
11
[DOI] 10.1016/j.cpccr.2023.100247.
2023
Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma.
Blood advances.
7(16):4608-4618
[DOI] 10.1182/bloodadvances.2022009426.
[PMID] 37126659.
2023
Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140(5):491-503.
Blood.
142(14)
[DOI] 10.1182/blood.2023022211.
[PMID] 37796516.
2023
Pattern of brexucabtagene autoleucel-related neurotoxicity on magnetic resonance imaging of the brain in a patient with relapsed/refractory B-cell acute lymphoblastic leukemia and prior leptomeningeal disease.
Radiology case reports.
18(3):1093-1098
[DOI] 10.1016/j.radcr.2022.12.053.
[PMID] 36660565.
2023
Repeatability of metabolic tumor burden and lesion glycolysis between clinical readers.
Frontiers in immunology.
14
[DOI] 10.3389/fimmu.2023.994520.
[PMID] 36875072.
2023
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Science advances.
9(38)
[DOI] 10.1126/sciadv.adg3919.
[PMID] 37738350.
2022
Viral Clearance with Neutrophil Recovery in a Patient with Active COVID-19 Infection and Refractory Acute Myeloid Leukemia Who Underwent Successful Reinduction with Cytarabine/Idarubicin.
Case reports in oncology.
15(2):705-712
[DOI] 10.1159/000525766.
[PMID] 36157697.
2021
Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.
Transplantation and cellular therapy.
27(7):620.e1-620.e9
[DOI] 10.1016/j.jtct.2021.03.026.
[PMID] 33798768.
2021
Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation.
Transplantation and cellular therapy.
27(11):940-948
[DOI] 10.1016/j.jtct.2021.07.023.
[PMID] 34329754.
2021
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
39(27):3034-3043
[DOI] 10.1200/JCO.21.00377.
[PMID] 34133196.
2021
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma.
Blood.
137(19):2621-2633
[DOI] 10.1182/blood.2020007445.
[PMID] 33512407.
2020
Diffuse Intrasinusoidal Hepatic Metastasis from Breast Cancer Presenting as Liver Failure: Effective and Rapid Treatment with Weekly Low-Dose Adriamycin.
The American journal of case reports.
21
[DOI] 10.12659/AJCR.924141.
[PMID] 32877389.
2020
High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma.
Blood advances.
4(14):3268-3276
[DOI] 10.1182/bloodadvances.2020001900.
[PMID] 32702097.
2017
Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention
Bone Marrow Transplantation.
52(7):1003-1009
[DOI] 10.1038/bmt.2017.63.
[PMID] 28368376.
Grants
Mar 2024
ACTIVE
AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPd), IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3)
Role: Principal Investigator
Funding: REGENERON PHARMACEUTICALS
Dec 2023
– Apr 2024
Computerized Neurotoxicity Screening for Patients with Relapsed/Refractory Lymphomas and Leukemia Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Role: Principal Investigator
Funding: KITE PHARMA
Sep 2023
ACTIVE
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion with Fludarabine, Cyclophosphamide, and ALLO-647, vs Fludarabine and Cyclophosphamide Alone, in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy.
Role: Principal Investigator
Funding: ALLOGENE THERAPEUTICS
Jun 2023
ACTIVE
Intermediate-Size Population Expanded Access Program (EAP) for cilta-cel Out-of-Specification (OOS) in Patients with Multiple Myeloma
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Feb 2023
ACTIVE
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Role: Principal Investigator
Funding: SWOG CLINICAL TRIALS INITIATIVE
Feb 2023
ACTIVE
A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma
Role: Principal Investigator
Funding: NRG ONCOLOGY FOU
via NATL INST OF HLTH NCI
Sep 2022
ACTIVE
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 Plus Rituximab in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin
Role: Principal Investigator
Funding: ARTIVA BIOTHERAPEUTICS
Jul 2022
ACTIVE
Evaluating soluble B-cell maturation antigen as a new serum marker of minimal residual disease in patients with Multiple Myeloma
Role: Principal Investigator
Funding: OCALA ROYAL DAMES FOR CANCER RESEARCH
Education
Fellowship in Blood & Marrow Transplant and Cellular Immunotherapy
2020-2021
·
Moffitt Cancer Center
Fellowship in Hematology-Oncology
2017-2020
·
University of South Florida
Residency in Internal Medicine
2014-2017
·
University of South Florida
Medical Degree
2010-2014
·
University of South Florida
Bachelor of Science in Biomedical Engineering
2004-2008
·
University of California – Irvine
Contact Details
Phones:
- Business:
- (352) 273-7832
Emails:
- Business:
- erin.dean@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100278
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100278
GAINESVILLE FL 32610